Vectura Group (VEC) Earns “Buy” Rating from Shore Capital

Shore Capital restated their buy rating on shares of Vectura Group (LON:VEC) in a research note issued to investors on Thursday.

Several other equities research analysts have also recently commented on VEC. Panmure Gordon reissued a buy rating and set a GBX 150 ($2.01) target price on shares of Vectura Group in a report on Thursday, November 9th. Numis Securities reissued a buy rating and set a GBX 205 ($2.74) target price on shares of Vectura Group in a report on Thursday, October 5th. JPMorgan Chase & Co. dropped their target price on Vectura Group from GBX 210 ($2.81) to GBX 180 ($2.41) and set an overweight rating on the stock in a report on Thursday, September 21st. Peel Hunt reissued a hold rating and set a GBX 160 ($2.14) target price on shares of Vectura Group in a report on Thursday, November 9th. Finally, Citigroup dropped their target price on Vectura Group from GBX 200 ($2.67) to GBX 180 ($2.41) and set a buy rating on the stock in a report on Monday, September 18th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of GBX 174 ($2.33).

Shares of Vectura Group (LON:VEC) opened at GBX 116.64 ($1.56) on Thursday. Vectura Group has a twelve month low of GBX 86.50 ($1.16) and a twelve month high of GBX 166.97 ($2.23).

ILLEGAL ACTIVITY NOTICE: This story was published by Equities Focus and is the sole property of of Equities Focus. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.equitiesfocus.com/2018/01/08/vectura-group-vec-earns-buy-rating-from-shore-capital.html.

About Vectura Group

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply